EGFR‐tyrosine kinase inhibitors (EGFR‐TKI) are widely used to treat metastatic NSCLC in patients bearing EGFR‐activating mutations, which are most commonly the L858R point mutation and the deletion of exon 19 (Rosell et al, 2012). Here, EGFR is linked to non-small cell lung carcinoma.